Pro Medicus Limited (ASX:PME) Chief Executive Officer Dr Sam Hupert has disclosed that the company achieved its second-biggest year for new contracts in FY26, recorded its busiest year for implementations, and completed six major contract renewals, according to a CEO interview filing released on 18 August 2026.

Key Points

  • Currency movements impacted FY26 revenue by just under $12 million and NPAT by $9.8 million due to a stronger Australian dollar.
  • The company achieved NPAT growth of more than 32% on a constant currency basis in FY26.
  • Pro Medicus completed six major contract renewals and had its busiest year for implementations, many of which came late in the second half.
  • The Visage platform is used by approximately 11% of the US market, including 11 of the top 20 US healthcare institutions.
  • The company's AI-driven reporting platform is in production in Europe and is planned for US release in the first half of calendar 2027.

FY26 Financial Results and Currency Effects

Dr Hupert stated that on a constant currency basis the company met its targets for increased revenue and increased profit after tax in FY26. The Australian dollar strengthened considerably over the past six months, which the CEO said had a more pronounced effect than in previous years. Revenue was impacted by just under $12 million and net profit after tax by $9.8 million as a result of currency translation. The company said it does hedge and benefits from a natural hedge given the United States represents its largest cost base. The CEO noted that a stronger Australian dollar reduces US-denominated expenses as well as translated revenues.

Contract Activity, Implementations and Revenue Timing

The filing states FY26 was the company's second-biggest year for new contracts after FY25, when the Trinity contract — described as the company's biggest contract to date — was won. Six major renewals were also completed during the period. Dr Hupert said many implementations occurred late in the second half of FY26 and therefore did not contribute materially to revenues during that year. The CEO stated these implementations are expected to provide a significant step-up in transaction revenue in FY27, as the company will receive a full 12 months of revenue from those contracts. The filing also noted clients are increasingly opting for more than one module, including all three modules described as "full stack," and with the cardiology module now available, some clients are described as "full stack +1."

Digital Pathology and AI-Driven Reporting Platform

Dr Hupert described digital pathology and the new AI-driven reporting platform as the next natural extensions of the company's "One Platform" strategy. The digital pathology solution is currently in production in Europe and the CEO said it will soon be brought to the United States. The AI-driven reporting platform, described as replacing legacy third-party reporting systems, is also in production in Europe. The company said it plans to bring the AI-driven reporting platform to the US in the first half of calendar 2027. Dr Hupert said both products are expected to generate complementary additional revenue streams for the company in time, consistent with the cardiology module.